AstraZeneca plc (LON:AZN) had its target price lowered by Bryan, Garnier & Co from GBX 5,400 ($70.49) to GBX 5,220 ($68.14) in a research report released on Tuesday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities analysts also recently issued reports on AZN. Jefferies Group raised their price target on AstraZeneca plc from GBX 3,900 ($50.91) to GBX 4,100 ($53.52) and gave the stock a hold rating in a research note on Tuesday, June 14th. BNP Paribas downgraded AstraZeneca plc to a neutral rating and set a GBX 5,200 ($67.88) target price on the stock. in a research report on Wednesday, September 14th. HSBC reiterated a hold rating and set a GBX 4,700 ($61.35) target price on shares of AstraZeneca plc in a research report on Thursday, August 11th. Beaufort Securities reiterated a hold rating on shares of AstraZeneca plc in a research report on Wednesday, August 10th. Finally, Societe Generale set a GBX 7,000 ($91.37) target price on AstraZeneca plc and gave the company a buy rating in a research report on Thursday, September 8th. Five investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of Hold and an average price target of GBX 4,937.91 ($64.46).

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Shares of AstraZeneca plc (LON:AZN) traded down 0.04% during trading on Tuesday, hitting GBX 5023.00. The stock had a trading volume of 1,040,959 shares. AstraZeneca plc has a 12 month low of GBX 3,680.00 and a 12 month high of GBX 5,505.00. The company’s market cap is GBX 63.54 billion. The stock has a 50 day moving average of GBX 5,009.44 and a 200 day moving average of GBX 4,418.92.

The company also recently declared a dividend, which was paid on Monday, September 12th. Stockholders of record on Thursday, August 11th were paid a dividend of GBX 68.70 ($0.90) per share. The ex-dividend date was Thursday, August 11th. This represents a dividend yield of 1.37%.

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.